Indication intelligence, analysis and sector perception

The Biostage (BSTG) Chronicles: could not complete the filing of its Form 10-K for the period ended 12/31/2020

March 31, 2021 8:19pm

Biostage (BSTG) could not complete the filing of its Form 10-K for the period ended 12/31/2020 due to disruptions in staffing… delaying their ability to obtain and compile the information required to be included in the Form 10-K, which delay could not be eliminated … without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended … BSTG will file its Form 10-K no later than the fifteenth calendar day following the prescribed due date. I haven’t been wrong, is there more to this “story line”? <read more>

Maintaining Sell, questions continue ...

Biostage (BSTG) closed down -$0.035 to $1.34 with 295 shares traded, after Tuesday’s -$0.125 to $1.375 with 758 shares traded, Monday’s flat at $1.50 with 25 shares traded, Friday’s flat with 10 shares traded and last Thursday’s flat at $1.50 with 39 shares traded.

Question#1: WILL BSTG’s management and BOD along with its auditor RSM US LLP explain IN DETAIL the reasons behind the late filing. Doesn’t it seem like a pretty “flimsy” excuse for NOT filing?

Question#2: WHY does the BOD and its newest member, Herman Sanchez support the current management team?

Question#3: Are their MORE issues related to accrued liabilities NOT being recorded and WHAT about the previously awarded PPP loan coming due?

Question#4: Is RSM US LLP still the auditor, notice there was NO statement in the SEC filing?

Hyperlink: SEC Form NT 10-K

SEC filing reference: https://app.quotemedia.com/data/downloadFiling? webmasterId=101533&ref=115764620&type=HTML&formType=NT+10-K&dateFiled=2021-03-31&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage

MINORITY PUBLIC shareholders are waiting, watching and weighting responses to MAINTAIN their RIGHTS.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.